Q#3 Please tell recent 5 studies titles, primary and secondary objectives.

1. A Randomized Phase 3 Study of MRTX949 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation

Primary Objective:

• Compare the effectiveness of MRTX949 and docetaxel in improving overall survival (OS).

Secondary Objectives:

• Evaluate progression-free survival (PFS) using RECIST v1.1.
• Assess objective response rate (ORR) and disease control rate (DCR).
• Measure the duration of response (DoR).
• Evaluate safety and tolerability.
• Analyze patient-reported outcomes (PROs) on quality of life (QoL).

2. An Open-label Phase 1b Study of ORIC-101 in Combination with Anticancer Therapy in Patients with Advanced or Metastatic Solid Tumors

Primary Objectives:

• Assess the safety and tolerability of ORIC-101 in combination with anticancer therapy.
• Determine the recommended Phase 2 dose (RP2D).

Secondary Objectives:

• Evaluate preliminary antitumor activity (ORR, PFS, OS).
• Study the pharmacokinetics (PK) of ORIC-101.

Exploratory Objectives:

• Identify biomarkers predicting response or resistance.
• Analyze patient-reported outcomes related to quality of life.

3. Phase 1 Trial of Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma

Primary Objective:

• Assess the safety and tolerability of the IFx-Hu2.0 vaccine.

Secondary Objectives:

• Evaluate immune responses (systemic and intralesional).
• Measure preliminary antitumor activity (RECIST 1.1 or iRECIST).

Exploratory Objectives:

• Identify biomarkers predicting response.
• Analyze changes in the tumor microenvironment.

4. A Phase-2 Open-label Multicentre Study of Single Agent Enzastaurin in Patients with Relapsed Cutaneous T-cell Lymphoma

Primary Objective:

• Measure the overall response rate (ORR) of Enzastaurin in patients with relapsed CTCL.

Secondary Objectives:

• Assess progression-free survival (PFS) and duration of response (DoR).
• Evaluate overall survival (OS).
• Determine the safety and tolerability of Enzastaurin.
• Explore biomarkers associated with response.

5. Evaluating the Efficacy and Safety of Pembrolizumab Versus Placebo in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Phase III Randomized Controlled TrialPrimary Objective:

• Assess the effectiveness of pembrolizumab compared to placebo in prolonging progression-free survival (PFS).

Secondary Objectives:

• Measure overall survival (OS).
• Evaluate the objective response rate (ORR) and duration of response (DoR).
• Assess the safety profile of pembrolizumab.

Exploratory Objectives:

• Explore the relationship between PD-L1 levels and treatment effectiveness.
• Analyze quality of life (QoL) using patient-reported data.